<DOC>
	<DOCNO>NCT00962585</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness S-equol menopausal patient hot flush night sweat .</brief_summary>
	<brief_title>Efficacy Safety S-equol Vasomotor Symptoms Menopausal Patients</brief_title>
	<detailed_description>The study randomize , double blind , multicenter , placebo control , parallel group , proof concept study compare efficacy , safety , acceptability 3 dose S-equol placebo menopausal patient vasomotor symptom . The study objective evaluation dose response 3 dose level AUS-131 ( S-equol ) placebo respect reduce mean number moderate severe vasomotor symptom 4 week treatment . The safety S-equol evaluate study .</detailed_description>
	<mesh_term>Equol</mesh_term>
	<criteria>12 month spontaneous amenorrhea , 6 month spontaneous amenorrhea serum follicle stimulate hormone ( FSH ) concentration &gt; 40 mIU/mL , 6 week postsurgical bilateral oophorectomy without hysterectomy , hysterectomy 2 ( measure 14 day apart ) serum FSH concentration &gt; 40 mIU/mL . Is likely experience least 50 moderate severe vasomotor symptom ( [ MSVS ] hot flush nocturnal sweating ) per week receive estrogen replacement therapy base history menopause , judgment investigator . Documented experience least 50 MSVS per week 14 day baseline period Randomization Visit ( Visit 3 ) , base patient diary entry ( calculate mean MSVS/week 14 day baseline period ) . If ≥ 40 year age , document negative mammogram normal clinical breast examination finding indicative breast malignancy . Has body mass index ( BMI ) &lt; 35.0 kg/m2 . Has know history allergic reaction clinically significant intolerance ingredient study drug . Received following : oral dermal estrogen/progestin selective estrogen receptor modulator ( SERM ) contain drug product therapy within 8 week Screening , injectable implantable estrogen/progestin therapy within 3 month Screening , hormone release intrauterine device Had unexplained otherwise abnormal vaginal bleeding within 6 month Screening . Has history , currently , follow condition : thrombophlebitis , thromboembolic disease , estrogen dependent neoplasia , carcinoma breast . Has history untreated uncontrolled endocrine disorder ( e.g. , hyperparathyroidism , uncontrolled hyperthyroidism ) . Has clinically significant unstable cardiac , respiratory , neurological , immunological , hematological , hepatic , renal , endocrine , gastric disease condition , opinion investigator , could compromise patient 's welfare , ability communicate study staff , otherwise contraindicate study participation . Has clinically significant depression severe psychiatric disturbance . Has active liver disease aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &gt; 3 time ULN , unexplained alkaline phosphatase &gt; 3 time ULN , total bilirubin &gt; 2 time ULN , renal insufficiency creatinine &gt; 1.7 mg/dL , clinically significant abnormal hemoglobin , white blood cell count , platelet count . Has endometrial thickness ≥ 4 mm . Has history indicative endometrial hyperplasia cancer . Shows presence manifest premalignant malignant disease except treated skin cancer ( except melanoma ) . Has know suspect history alcoholism drug abuse misuse within past 5 year . Has rest systolic blood pressure ( BP ) &gt; 160 mmHg &lt; 90 mmHg , diastolic BP &gt; 90 mmHg &lt; 60 mmHg Screening . Has history smoke 5 cigarette daily within year Screening . Has test positive urine drug screen . Patients test positive Screening produce documentation physician medication cause positive test may consider study enrollment discretion investigator . Has significant difficulty swallow capsule unable tolerate oral medication . Has participate another clinical trial receive investigational drug device investigational therapy within 30 day Screening . Has disorder affect gastrointestinal absorption .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>